Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2267-2274

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Data Supplement
Right arrow Data Supplement
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vergnes, L.
Right arrow Articles by Ochoa, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vergnes, L.
Right arrow Articles by Ochoa, A.
Related Collections
Right arrow Animal models of human disease
Right arrow Gene expression
Right arrow Genetically altered mice
Right arrow Lipid and lipoprotein metabolism
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2267.)
© 2000 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Expression of Human Apolipoprotein A-I/C-III/A-IV Gene Cluster in Mice Induces Hyperlipidemia but Reduces Atherogenesis

Laurent Vergnes; Nadine Baroukh; Maria A. Ostos; Graciela Castro; Nicolas Duverger; M. Nazeem Nanjee; Jamila Najib; Jean-Charles Fruchart; Norman E. Miller; Mario M. Zakin; Alberto Ochoa

From the Unité d’Expression des Gènes Eucaryotes, Institut Pasteur (L.V., N.B., M.A.O., M.M.Z., A.O.), Paris, France; U 325 Inserm Institut Pasteur (G.C., J.N., J.-C.F.), Lille, France; Rhone-Poulenc Rorer (N.D.), Vitry sur Seine, France; Institut National de la Recherche Agronomique (A.O.) Jouy-en-Josas, France; and St. Bartholomew’s and the Royal London School of Medicine and Dentistry (M.N.N., N.E.M.), London, UK.

Correspondence to Alberto Ochoa, Unité d’Expression des Gènes Eucaryotes, Institut Pasteur, 28 rue du Dr. Roux, 75724, Paris cedex 15, France. E-mail aochoa{at}pasteur.fr

Abstract—The apolipoprotein (apo)A-I/C-III/A-IV gene cluster is involved in lipid metabolism and atherosclerosis. Overexpression of apoC-III in mice causes hypertriglyceridemia and induces atherogenesis, whereas overexpression of apoA-I or apoA-IV increases cholesterol in plasma high density lipoprotein (HDL) and protects against atherosclerosis. Each gene has been studied alone in transgenic mice but not in combination as the entire cluster. To determine which phenotype is produced by the expression of the entire gene cluster, transgenic mice were generated with a 33-kb human DNA fragment. The results showed that the transgene contained the necessary elements to direct hepatic and intestinal expression of the 3 genes. In the pooled data, plasma concentrations were 257±9, 7.1±0.5, and 1.0±0.2 mg/dL for human apoA-I, apoC-III, and apoA-IV, respectively (mean±SEM). Concentrations of these apolipoproteins were higher in males than in females. Human apoA-I and apoC-III concentrations were positively correlated, suggesting that they are coregulated. Transgenic mice exhibited gross hypertriglyceridemia and accumulation of apoB48–containing triglyceride-rich lipoproteins. Plasma triglyceride and cholesterol concentrations were correlated positively with human apoC-III concentration, and HDL cholesterol was correlated with apoA-I concentration. In an apoE-deficient background, despite being markedly hypertriglyceridemic, cluster transgenic animals compared with nontransgenic animals showed a 61% reduction in atherosclerosis. This suggests that apoA-I and/or apoA-IV can protect against atherosclerosis even in the presence of severe hyperlipidemia. These mice provide a new model for studies of the regulation of the 3 human genes in combination.


Key Words: transgenic mice • hypertriglyceridemia • cholesterol • lipoproteins • atherosclerosis




This article has been cited by other articles:


Home page
J. Lipid Res.Home page
H. Mezdour, G. Larigauderie, G. Castro, G. Torpier, J. Fruchart, M. Nowak, J.-C. Fruchart, M. Rouis, and N. Maeda
Characterization of a new mouse model for human apolipoprotein A-I/C-III/A-IV deficiency
J. Lipid Res., May 1, 2006; 47(5): 912 - 920.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
J. Shepherd
Raising HDL-cholesterol and lowering CHD risk: does intervention work?
Eur. Heart J. Suppl., July 1, 2005; 7(suppl_F): F15 - F22.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. Merkel, B. Loeffler, M. Kluger, N. Fabig, G. Geppert, L. A. Pennacchio, A. Laatsch, and J. Heeren
Apolipoprotein AV Accelerates Plasma Hydrolysis of Triglyceriderich Lipoproteins by Interaction with Proteoglycan-bound Lipoprotein Lipase
J. Biol. Chem., June 3, 2005; 280(22): 21553 - 21560.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
G. C. Shearer, J. W. Newman, B. D. Hammock, and G. A. Kaysen
Graded Effects of Proteinuria on HDL Structure in Nephrotic Rats
J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1309 - 1319.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Gao, Y. Wei, Y. Huang, D. Liu, G. Liu, M. Wu, L. Wu, Q. Zhang, Z. Zhang, R. Zhang, et al.
The Expression of Intact and Mutant Human apoAI/CIII/AIV/AV Gene Cluster in Transgenic Mice
J. Biol. Chem., April 1, 2005; 280(13): 12559 - 12566.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
N. Baroukh, E. Bauge, J. Akiyama, J. Chang, V. Afzal, J.-C. Fruchart, E. M. Rubin, J. Fruchart-Najib, and L. A. Pennacchio
Analysis of Apolipoprotein A5, C3, and Plasma Triglyceride Concentrations in Genetically Engineered Mice
Arterioscler. Thromb. Vasc. Biol., July 1, 2004; 24(7): 1297 - 1302.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
W.-m. R. Wong, E. Hawe, L. K. Li, G. J. Miller, V. Nicaud, L. A. Pennacchio, S. E. Humphries, and P. J. Talmud
Apolipoprotein AIV Gene Variant S347 Is Associated With Increased Risk of Coronary Heart Disease and Lower Plasma Apolipoprotein AIV Levels
Circ. Res., May 16, 2003; 92(9): 969 - 975.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Gervais, S. Pons, A. Nicoletti, C. Cosson, J.-F. Giudicelli, and C. Richer
Fluvastatin Prevents Renal Dysfunction and Vascular NO Deficit in Apolipoprotein E-Deficient Mice
Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 183 - 189.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
M. A. Ostos, D. Recalde, N. Baroukh, A. Callejo, M. Rouis, G. Castro, and M. M. Zakin
Fructose Intake Increases Hyperlipidemia and Modifies Apolipoprotein Expression in Apolipoprotein AI-CIII-AIV Transgenic Mice
J. Nutr., May 1, 2002; 132(5): 918 - 923.
[Abstract] [Full Text] [PDF]